8-K: Crinetics Pharmaceuticals Announces Positive Phase 2 Results for Atumelnant in Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals reports successful topline results from its Phase 2 trial of atumelnant, showing significant reductions in key biomarkers and improvements in clinical signs and symptoms for patients with congenital adrenal hyperplasia (CAH).

Summary

• Crinetics Pharmaceuticals has announced positive topline results from its Phase 2 trial of atumelnant, a novel oral ACTH receptor antagonist, for the treatment of congenital adrenal hyperplasia (CAH).
• The study, named TouCAHn, was an open-label trial involving 28 patients with classic CAH across three dose cohorts (40mg, 80mg, and 120mg) over a 12-week period.
• The primary endpoint was the change from baseline in morning serum androstenedione (A4) levels, and the secondary endpoint was the change in 17-hydroxyprogesterone (17-OHP) levels.
• Atumelnant demonstrated rapid, substantial, and sustained statistically significant reductions in A4 levels across all doses, with up to an 80% mean reduction observed.
• Significant reductions in 17-OHP levels were also achieved, confirming the drug's effectiveness.
• The treatment also showed meaningful improvements in clinical signs and symptoms of CAH, including normalization of testosterone in the majority of female participants, resumption of menses in some, and resolution of androgen-mediated polycythemia in most impacted participants.
• Atumelnant was generally well-tolerated, with no treatment-related severe or serious adverse events reported.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive results from a Phase 2 trial, with strong efficacy and a good safety profile. The company's plans for Phase 3 trials and further development indicate a high level of confidence in the drug's potential.

Positives

• Atumelnant showed rapid and substantial reductions in key biomarkers, A4 and 17-OHP, indicating effective disease control.
• The drug demonstrated a dose-response relationship, with higher doses leading to greater reductions in A4 levels.
• Clinical improvements were observed in multiple signs and symptoms of CAH, including hormonal normalization and resolution of polycythemia.
• The treatment was well-tolerated, with no severe or serious adverse events, suggesting a favorable safety profile.
• The results support the initiation of a Phase 3 pivotal trial in adults and a Phase 2b/3 trial in pediatric patients.

Negatives

• The most common treatment-emergent adverse events included headache and fatigue, although these were generally mild to moderate and transient.
• One participant at the 120mg dose experienced increases in AST/ALT levels, although these returned to baseline off the study drug.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the possibility that the reported data may change after a more comprehensive review.
• There is a risk that the FDA and other regulatory authorities may not agree with the company's interpretation of the results.
• Unexpected adverse side effects or inadequate efficacy of the drug could limit its development and commercialization.
• Clinical studies may not proceed as expected, and the timing of regulatory review is uncertain.

Future Outlook

Crinetics plans to initiate a global Phase 3 pivotal trial for adults with CAH in the first half of 2025 and simultaneously prepare to start a Phase 2b/3 trial in pediatric patients this year. The company also intends to submit INDs for four additional candidates now in first-in-human enabling studies.

Management Comments

• Scott Struthers, Ph.D., founder and CEO of Crinetics, stated that the results show atumelnant not only lowered key biomarkers but also had a significant impact on the signs and symptoms of CAH.
• Dr. Alan Krasner, M.D., chief endocrinologist of Crinetics, noted that the study demonstrated atumelnant was well-tolerated and resulted in a rapid and robust reduction of adrenal androgen levels, leading to meaningful improvements in long-term medical challenges.

Industry Context

This announcement is significant as it highlights the potential of a novel oral ACTH receptor antagonist in treating CAH, a condition with limited treatment options. The positive results position Crinetics as a leader in the endocrine therapeutics space, potentially impacting the treatment landscape for CAH and related conditions.

Comparison to Industry Standards

• Current treatments for CAH primarily involve glucocorticoid replacement therapy, which can have significant side effects. Atumelnant's approach of directly targeting the ACTH receptor offers a novel mechanism of action.
• The reported 80% reduction in A4 levels is a substantial improvement compared to the results seen with existing therapies, which often struggle to achieve complete hormonal control.
• The rapid onset of action and the improvements in clinical signs and symptoms, such as the resumption of menses and resolution of polycythemia, are also notable advantages over current treatment options.
• While direct comparisons to other investigational drugs are limited due to the novelty of the approach, the results suggest that atumelnant could become a best-in-class treatment for CAH.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical results and the company's plans for further development.
• Patients with CAH stand to benefit from a new treatment option that has shown significant efficacy and a favorable safety profile.
• Employees of Crinetics may experience increased job security and opportunities for growth due to the company's progress.
• The positive results may also enhance the company's reputation and attract potential partners and investors.

Next Steps

• Initiate a Phase 3 pivotal trial in the adult CAH population in the first half of 2025.
• Start a Phase 2/3 pivotal trial in the pediatric CAH population.
• Submit INDs for four additional drug candidates currently in first-in-human enabling studies.

Key Dates

Keywords

Congenital Adrenal Hyperplasia, CAH, Atumelnant, ACTH Receptor Antagonist, Androstenedione, 17-hydroxyprogesterone, Endocrine Disease, Phase 2 Trial, Clinical Trial, Biomarkers